The DOI matches its Crossref record; 179 of the 179 references it cites were found in a registry or an index.
Antibiotic resistance in Staphylococcus aureus. Current status and future prospects
Open accessAbstract
The major targets for antibiotics in staphylococci are (i) the cell envelope, (ii) the ribosome and (iii) nucleic acids. Several novel targets emerged from recent targeted drug discovery programmes including the ClpP protease and FtsZ from the cell division machinery. Resistance can either develop by horizontal transfer of resistance determinants encoded by mobile genetic elements viz plasmids, transposons and the staphylococcal cassette chromosome or by mutations in chromosomal genes. Horizontally acquired resistance can occur by one of the following mechanisms: (i) enzymatic drug modification and inactivation, (ii) enzymatic modification of the drug binding site, (iii) drug efflux, (iv) bypass mechanisms involving acquisition of a novel drug-resistant target, (v) displacement of the drug to protect the target. Acquisition of resistance by mutation can result from (i) alteration of the drug target that prevents the inhibitor from binding, (ii) derepression of chromosomally encoded multidrug resistance efflux pumps and (iii) multiple stepwise mutations that alter the structure and composition of the cell wall and/or membrane to reduce drug access to its target. This review focuses on development of resistance to currently used antibiotics and examines future prospects for new antibiotics and informed use of drug combinations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chopra, I., & Roberts, M. (2001) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.65.2.232-260.2001 · Cited by 4,517
Waves of resistance: Staphylococcus aureus in the antibiotic era
Chambers, H. F., & DeLeo, F. R. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2200 · Cited by 2,718
A new antibiotic kills pathogens without detectable resistance
Ling, L. L., Schneider, T., Peoples, A. J., Spoering, A. L., Engels, I., Conlon, B. P., Mueller, A., Schäberle, T. F., Hughes, D. E., Epstein, S., et al. (2015) · Nature · doi:10.1038/nature14098 · Cited by 2,428
Lewis, K. (2010) · Annual Review of Microbiology · doi:10.1146/annurev.micro.112408.134306 · Cited by 1,858
Wang, J. C. (1996) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.65.070196.003223 · Cited by 1,832
Microbiological effects of sublethal levels of antibiotics
Andersson, D. I., & Hughes, D. (2014) · Nature Reviews Microbiology · doi:10.1038/nrmicro3270 · Cited by 1,757
A brief history of the antibiotic era: lessons learned and challenges for the future
Aminov, R. I. (2010) · Frontiers in Microbiology · doi:10.3389/fmicb.2010.00134 · Cited by 1,628
Structural Mechanism for Rifampicin Inhibition of Bacterial RNA Polymerase
Campbell, E. A., Korzheva, N., Mustaev, A., Murakami, K., Nair, S., Goldfarb, A., & Darst, S. A. (2001) · Cell · doi:10.1016/s0092-8674(01)00286-0 · Cited by 1,556 · cited 1×
“does not prevent RNA polymerase from binding to the promoter and initiating transcription (Campbell et al. 2001).”
BackgroundMultidrug-resistance efflux pumps ? not just for resistance
Piddock, L. J. V. (2006) · Nature Reviews Microbiology · doi:10.1038/nrmicro1464 · Cited by 1,522
Community-associated meticillin-resistant Staphylococcus aureus
DeLeo, F. R., Otto, M., Kreiswirth, B. N., & Chambers, H. F. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61999-1 · Cited by 1,506
Aminoglycoside modifying enzymes
Ramirez, M. S., & Tolmasky, M. E. (2010) · Drug Resistance Updates · doi:10.1016/j.drup.2010.08.003 · Cited by 1,464
Antimicrobial resistance: the example of Staphylococcus aureus
Lowy, F. D. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18535 · Cited by 1,445
Clinical relevance of the ESKAPE pathogens
Pendleton, J. N., Gorman, S. P., & Gilmore, B. F. (2013) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.13.12 · Cited by 1,423
Challenges of Antibacterial Discovery
Silver, L. L. (2011) · Clinical Microbiology Reviews · doi:10.1128/cmr.00030-10 · Cited by 1,376
Ribosome-targeting antibiotics and mechanisms of bacterial resistance
Wilson, D. N. (2014) · Nature Reviews Microbiology · doi:10.1038/nrmicro3155 · Cited by 1,054
Vancomycin Resistance in Gram-Positive Cocci
Courvalin, P. (2006) · Clinical Infectious Diseases · doi:10.1086/491711 · Cited by 1,028 · cited 3×
“lipid IImoleculewithD-lactate replacingD-Ala5 (Courvalin 2006; Zeng et al. 2016).”
BackgroundErythromycin resistance by ribosome modification
Weisblum, B. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.3.577 · Cited by 1,008
Howden, B. P., Davies, J. K., Johnson, P. D. R., Stinear, T. P., & Grayson, M. L. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00042-09 · Cited by 962
Hartman, B. J., & Tomasz, A. (1984) · Journal of Bacteriology · doi:10.1128/jb.158.2.513-516.1984 · Cited by 890
Nomenclature for Macrolide and Macrolide-Lincosamide-Streptogramin B Resistance Determinants
Roberts, M. C., Sutcliffe, J., Courvalin, P., Jensen, L. B., Rood, J., & Seppala, H. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.12.2823 · Cited by 874
Platensimycin is a selective FabF inhibitor with potent antibiotic properties
Wang, J., Soisson, S. M., Young, K., Shoop, W., Kodali, S., Galgoci, A., Painter, R., Parthasarathy, G., Tang, Y. S., Cummings, R., et al. (2006) · Nature · doi:10.1038/nature04784 · Cited by 812
Bacterial cell division: assembly, maintenance and disassembly of the Z ring
Adams, D. W., & Errington, J. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2198 · Cited by 811
Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis
Seung, K. J., Keshavjee, S., & Rich, M. L. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a017863 · Cited by 805
THE CATALYTIC MECHANISM AND STRUCTURE OF THYMIDYLATE SYNTHASE
Carreras, C. W., & Santi, D. V. (1995) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.64.070195.003445 · Cited by 768
Mechanisms of drug resistance: quinolone resistance
Hooper, D. C., & Jacoby, G. A. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12830 · Cited by 716
Long, K. S., Poehlsgaard, J., Kehrenberg, C., Schwarz, S., & Vester, B. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00131-06 · Cited by 708
Toxin-antitoxin systems in bacterial growth arrest and persistence
Page, R., & Peti, W. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2044 · Cited by 702
Arbeit, R. D., Maki, D., Tally, F. P., Campanaro, E., Eisenstein, B. I., & Daptomycin 98-01 and 99-01 Investigators (2004) · Clinical Infectious Diseases · doi:10.1086/420818 · Cited by 689
Activated ClpP kills persisters and eradicates a chronic biofilm infection
Conlon, B. P., Nakayasu, E. S., Fleck, L. E., LaFleur, M. D., Isabella, V. M., Coleman, K., Leonard, S. N., Smith, R. D., Adkins, J. N., & Lewis, K. (2013) · Nature · doi:10.1038/nature12790 · Cited by 672
Persister formation in Staphylococcus aureus is associated with ATP depletion
Conlon, B. P., Rowe, S. E., Gandt, A. B., Nuxoll, A. S., Donegan, N. P., Zalis, E. A., Clair, G., Adkins, J. N., Cheung, A. L., & Lewis, K. (2016) · Nature Microbiology · doi:10.1038/nmicrobiol.2016.51 · Cited by 671
Mechanisms of Methicillin Resistance in Staphylococcus aureus
Peacock, S. J., & Paterson, G. K. (2015) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060614-034516 · Cited by 656
Sulfonamide resistance: mechanisms and trends.
Sköld, O. (2000) · Drug Resistance Updates · doi:10.1054/drup.2000.0146 · Cited by 647 · cited 1×
“This shuts off a precursor of folic acid resulting in a slow acting, bacteristatic affect (Skold 2000).”
BackgroundCho, H., Uehara, T., & Bernhardt, T. G. (2014) · Cell · doi:10.1016/j.cell.2014.11.017 · Cited by 642
Mechanisms of vancomycin resistance in Staphylococcus aureus
Gardete, S., & Tomasz, A. (2014) · Journal of Clinical Investigation · doi:10.1172/jci68834 · Cited by 565
Mobile genetic elements of Staphylococcus aureus
Malachowa, N., & DeLeo, F. R. (2010) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-010-0389-4 · Cited by 560
Wang, Y., Lv, Y., Cai, J., Schwarz, S., Cui, L., Hu, Z., Zhang, R., Li, J., Zhao, Q., He, T., et al. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv116 · Cited by 546
Mechanism of Triclosan Inhibition of Bacterial Fatty Acid Synthesis
Heath, R. J., Rubin, J. R., Holland, D. R., Zhang, E., Snow, M. E., & Rock, C. O. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.16.11110 · Cited by 542
Tetracycline antibiotics and resistance mechanisms
Nguyen, F., Starosta, A. L., Arenz, S., Sohmen, D., Dönhöfer, A., & Wilson, D. N. (2014) · Biological Chemistry · doi:10.1515/hsz-2013-0292 · Cited by 528
Plasmid-determined resistance to antimicrobial drugs and toxic metal ions in bacteria
Foster, T. J. (1983) · Microbiological Reviews · doi:10.1128/mmbr.47.3.361-409.1983 · Cited by 502
Self-citationBacterial Fatty Acid Biosynthesis: Targets for Antibacterial Drug Discovery
Campbell, J. W., & Cronan, J. E. (2001) · Annual Review of Microbiology · doi:10.1146/annurev.micro.55.1.305 · Cited by 479
The emergence of mecC methicillin-resistant Staphylococcus aureus
Paterson, G. K., Harrison, E. M., & Holmes, M. A. (2013) · Trends in Microbiology · doi:10.1016/j.tim.2013.11.003 · Cited by 470
An Inhibitor of FtsZ with Potent and Selective Anti-Staphylococcal Activity
Haydon, D. J., Stokes, N. R., Ure, R., Galbraith, G., Bennett, J. M., Brown, D. R., Baker, P. J., Barynin, V. V., Rice, D. W., Sedelnikova, S. E., et al. (2008) · Science · doi:10.1126/science.1159961 · Cited by 452
Ribosomal Protection Proteins and Their Mechanism ofTetracyclineResistance
Connell, S. R., Tracz, D. M., Nierhaus, K. H., & Taylor, D. E. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.12.3675-3681.2003 · Cited by 449
Triclosan: a widely used biocide and its link to antibiotics
Schweizer, H. (2001) · FEMS Microbiology Letters · doi:10.1016/s0378-1097(01)00273-7 · Cited by 447
Lim, D., & Strynadka, N. C. J. (2002) · Nature Structural Biology · doi:10.1038/nsb858 · Cited by 442
The Quinolones: Past, Present, and Future
Andriole, V. T. (2005) · Clinical Infectious Diseases · doi:10.1086/428051 · Cited by 428
Kinship and Diversification of Bacterial Penicillin-Binding Proteins and β-Lactamases
Massova, I., & Mobashery, S. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.1.1 · Cited by 422
Kehrenberg, C., & Schwarz, S. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.4.1156-1163.2006 · Cited by 398
Pinho, M. G., de Lencastre, H., & Tomasz, A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191260798 · Cited by 384
Resistance to Linezolid Caused by Modifications at Its Binding Site on the Ribosome
Long, K. S., & Vester, B. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05702-11 · Cited by 375
Howden, B. P., McEvoy, C. R. E., Allen, D. L., Chua, K., Gao, W., Harrison, P. F., Bell, J., Coombs, G., Bennett-Wood, V., Porter, J. L., et al. (2011) · PLoS Pathogens · doi:10.1371/journal.ppat.1002359 · Cited by 370
Ernst, C. M., Staubitz, P., Mishra, N. N., Yang, S.-J., Hornig, G., Kalbacher, H., Bayer, A. S., Kraus, D., & Peschel, A. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000660 · Cited by 368
Utsui, Y., & Yokota, T. (1985) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.28.3.397 · Cited by 365
Kehrenberg, C., Schwarz, S., Jacobsen, L., Hansen, L. H., & Vester, B. (2005) · Molecular Microbiology · doi:10.1111/j.1365-2958.2005.04754.x · Cited by 333
The A-Z of bacterial translation inhibitors
Wilson, D. N. (2009) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409230903307311 · Cited by 322
Fluoroquinolone resistance among Gram-positive cocci
Hooper, D. C. (2002) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(02)00369-9 · Cited by 320
Bayer, A. S., Schneider, T., & Sahl, H. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2012.06819.x · Cited by 311
Staphylococcal Cell Wall: Morphogenesis and Fatal Variations in the Presence of Penicillin
Giesbrecht, P., Kersten, T., Maidhof, H., & Wecke, J. (1998) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.62.4.1371-1414.1998 · Cited by 304
Nesme, J., & Simonet, P. (2015) · Environmental Microbiology · doi:10.1111/1462-2920.12631 · Cited by 303
MgrA Is a Multiple Regulator of Two New Efflux Pumps in Staphylococcus aureus
Truong-Bolduc, Q. C., Dunman, P. M., Strahilevitz, J., Projan, S. J., & Hooper, D. C. (2005) · Journal of Bacteriology · doi:10.1128/jb.187.7.2395-2405.2005 · Cited by 296
Davis, B. D., Chen, L. L., & Tai, P. C. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.16.6164 · Cited by 293
How to get (a)round: mechanisms controlling growth and division of coccoid bacteria
Pinho, M. G., Kjos, M., & Veening, J.-W. (2013) · Nature Reviews Microbiology · doi:10.1038/nrmicro3088 · Cited by 289
Liu, J., Chen, D., Peters, B. M., Li, L., Li, B., Xu, Z., & Shirliff, M. E. (2016) · Microbial Pathogenesis · doi:10.1016/j.micpath.2016.10.028 · Cited by 285
ABC-F Proteins Mediate Antibiotic Resistance through Ribosomal Protection
Sharkey, L. K. R., Edwards, T. A., & O’Neill, A. J. (2016) · mBio · doi:10.1128/mbio.01975-15 · Cited by 284
Otero, L. H., Rojas-Altuve, A., Llarrull, L. I., Carrasco-López, C., Kumarasiri, M., Lastochkin, E., Fishovitz, J., Dawley, M., Hesek, D., Lee, M., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1300118110 · Cited by 281
Biological cost and compensatory evolution in fusidic acid‐resistant Staphylococcus aureus
Nagaev, I., Björkman, J., Andersson, D. I., & Hughes, D. (2001) · Molecular Microbiology · doi:10.1046/j.1365-2958.2001.02389.x · Cited by 257
Dhand, A., Bayer, A. S., Pogliano, J., Yang, S.-J., Bolaris, M., Nizet, V., Wang, G., & Sakoulas, G. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir340 · Cited by 252 · cited 2×
“Indeed, combinations of daptomycin and β-lactams act synergistically on MRSA (the so-called see-saw effect) and have been used successfully to treat persistent infections caused by Dapr MRSA (Dhand et al. 2011; Dhand and Sakoulas 2014; Sakoulas et al. 2014).”
BackgroundA Proteolytic Transmembrane Signaling Pathway and Resistance to β-Lactams in Staphylococci
Zhang, H. Z., Hackbarth, C. J., Chansky, K. M., & Chambers, H. F. (2001) · Science · doi:10.1126/science.1055144 · Cited by 252
Restoring Methicillin-Resistant Staphylococcus aureus Susceptibility to β-Lactam Antibiotics
Tan, C. M., Therien, A. G., Lu, J., Lee, S. H., Caron, A., Gill, C. J., Lebeau-Jacob, C., Benton-Perdomo, L., Monteiro, J. M., Pereira, P. M., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003592 · Cited by 241
Aminoglycoside-modifying enzymes
Wright, G. D. (1999) · Current Opinion in Microbiology · doi:10.1016/s1369-5274(99)00007-7 · Cited by 241
Ernst, C. M., & Peschel, A. (2011) · Molecular Microbiology · doi:10.1111/j.1365-2958.2011.07576.x · Cited by 238
McAleese, F., Petersen, P., Ruzin, A., Dunman, P. M., Murphy, E., Projan, S. J., & Bradford, P. A. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.5.1865-1871.2005 · Cited by 233
Inhibition of Folate Biosynthesis and Function as a Basis for Chemotherapy
Hitchings, G. H., & Burchall, J. J. (1965) · Advances in Enzymology - and Related Areas of Molecular Biology · doi:10.1002/9780470122723.ch9 · Cited by 232
Mechanism of Action and Resistance to Daptomycin in Staphylococcus aureus and Enterococci
Miller, W. R., Bayer, A. S., & Arias, C. A. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026997 · Cited by 227
Aubry-Damon, H., Soussy, C.-J., & Courvalin, P. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.10.2590 · Cited by 225
Russell, A. D. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh171 · Cited by 223
Structural basis for TetM-mediated tetracycline resistance
Dönhöfer, A., Franckenberg, S., Wickles, S., Berninghausen, O., Beckmann, R., & Wilson, D. N. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1208037109 · Cited by 217
den Heijer, C. D., van Bijnen, E. M., Paget, W. J., Pringle, M., Goossens, H., Bruggeman, C. A., Schellevis, F. G., & Stobberingh, E. E. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70036-7 · Cited by 216
Argudín, M. A., Tenhagen, B.-A., Fetsch, A., Sachsenröder, J., Käsbohrer, A., Schroeter, A., Hammerl, J. A., Hertwig, S., Helmuth, R., Bräunig, J., et al. (2011) · Applied and Environmental Microbiology · doi:10.1128/aem.02260-10 · Cited by 215
An oxidation-sensing mechanism is used by the global regulator MgrA in Staphylococcus aureus
Chen, P. R., Bae, T., Williams, W. A., Duguid, E. M., Rice, P. A., Schneewind, O., & He, C. (2006) · Nature Chemical Biology · doi:10.1038/nchembio820 · Cited by 213
Approved Glycopeptide Antibacterial Drugs: Mechanism of Action and Resistance
Zeng, D., Debabov, D., Hartsell, T. L., Cano, R. J., Adams, S., Schuyler, J. A., McMillan, R., & Pace, J. L. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026989 · Cited by 211
Jenner, L., Starosta, A. L., Terry, D. S., Mikolajka, A., Filonava, L., Yusupov, M., Blanchard, S. C., Wilson, D. N., & Yusupova, G. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1216691110 · Cited by 204
Genetics of Antimicrobial Resistance in Staphylococcus Aureus
Jensen, S. O., & Lyon, B. R. (2009) · Future Microbiology · doi:10.2217/fmb.09.30 · Cited by 202
Thurlow, L. R., Joshi, G. S., Clark, J. R., Spontak, J. S., Neely, C. J., Maile, R., & Richardson, A. R. (2013) · Cell Host & Microbe · doi:10.1016/j.chom.2012.11.012 · Cited by 201
Structure and function of the dihydropteroate synthase from staphylococcus aureus
Hampele, I. C., D’Arcy, A., Dale, G. E., Kostrewa, D., Nielsen, J., Oefner, C., Page, M. G. P., Schönfeld, H.-J., Stüber, D., & Then, R. L. (1997) · Journal of Molecular Biology · doi:10.1006/jmbi.1997.0944 · Cited by 201
Brickner, S. J., Barbachyn, M. R., Hutchinson, D. K., & Manninen, P. R. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800038g · Cited by 196
Evolution of community- and healthcare-associated methicillin-resistant Staphylococcus aureus
Uhlemann, A.-C., Otto, M., Lowy, F. D., & DeLeo, F. R. (2014) · Infection, Genetics and Evolution · doi:10.1016/j.meegid.2013.04.030 · Cited by 194
Resistance to and synthesis of the antibiotic mupirocin
Thomas, C. M., Hothersall, J., Willis, C. L., & Simpson, T. J. (2010) · Nature Reviews Microbiology · doi:10.1038/nrmicro2278 · Cited by 187
Andreu, J. M., Schaffner-Barbero, C., Huecas, S., Alonso, D., Lopez-Rodriguez, M. L., Ruiz-Avila, L. B., Núñez-Ramírez, R., Llorca, O., & Martín-Galiano, A. J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.094722 · Cited by 184
Howden, B. P., & Grayson, M. L. (2006) · Clinical Infectious Diseases · doi:10.1086/499365 · Cited by 182
Sakoulas, G., Moise, P. A., Casapao, A. M., Nonejuie, P., Olson, J., Okumura, C. Y. M., Rybak, M. J., Kullar, R., Dhand, A., Rose, W. E., et al. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.05.061 · Cited by 181
NorC, a New Efflux Pump Regulated by MgrA of Staphylococcus aureus
Truong, Q. C., Strahilevitz, J., & Hooper, D. C. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.3.1104-1107.2006 · Cited by 181
Is bacterial fatty acid synthesis a valid target for antibacterial drug discovery?
Parsons, J. B., & Rock, C. O. (2011) · Current Opinion in Microbiology · doi:10.1016/j.mib.2011.07.029 · Cited by 176
Schwarz, Š., Shen, J., Kadlec, K., Wang, Y., Michael, G. B., Feßler, A. T., & Vester, B. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a027037 · Cited by 176
Dale, G. E., Broger, C., D' Arcy, A., Hartman, P. G., DeHoogt, R., Jolidon, S., Kompis, I., Labhardt, A. M., Langen, H., Locher, H., et al. (1997) · Journal of Molecular Biology · doi:10.1006/jmbi.1996.0770 · Cited by 175
Antibiotics currently used in the treatment of infections caused by Staphylococcus aureus
RAYNER, C., & MUNCKHOF, W. J. (2005) · Internal Medicine Journal · doi:10.1111/j.1444-0903.2005.00976.x · Cited by 174
Ceftaroline: A Novel Cephalosporin with Activity against Methicillin-resistant Staphylococcus aureus
Saravolatz, L. D., Stein, G. E., & Johnson, L. B. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir147 · Cited by 173
Discovery of a Novel and Potent Class of FabI-Directed Antibacterial Agents
Payne, D. J., Miller, W. H., Berry, V., Brosky, J., Burgess, W. J., Chen, E., DeWolf, W. E., Fosberry, A. P., Greenwood, R., Head, M. S., et al. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.10.3118-3124.2002 · Cited by 170
Bacterial Protein Synthesis as a Target for Antibiotic InhibitionPreprint
Arenz, S., & Wilson, D. N. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a025361 · Cited by 170
FERNANDES, P. B. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a025437 · Cited by 165
Ding, Y., Onodera, Y., Lee, J. C., & Hooper, D. C. (2008) · Journal of Bacteriology · doi:10.1128/jb.00655-08 · Cited by 164
Rudkin, J. K., Edwards, A. M., Bowden, M. G., Brown, E. L., Pozzi, C., Waters, E. M., Chan, W. C., Williams, P., O’Gara, J. P., & Massey, R. C. (2012) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir845 · Cited by 164
Long, S. W., Olsen, R. J., Mehta, S. C., Palzkill, T. G., Cernoch, P. L., Perez, K. K., Musick, W. L., Rosato, A. E., & Musser, J. M. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03622-14 · Cited by 161
Paul, M., Bishara, J., Yahav, D., Goldberg, E., Neuberger, A., Ghanem‐Zoubi, N., Dickstein, Y., Nseir, W., Dan, M., & Leibovici, L. (2015) · BMJ · doi:10.1136/bmj.h2219 · Cited by 158
Formation of the ribosome-G factor-GDP complex in the presence of fusidic acid
Bodley, J. W., Zieve, F. J., Lin, L., & Zieve, S. T. (1969) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(69)90934-6 · Cited by 158
Hershberger, E., Donabedian, S., Konstantinou, K., & Zervos, M. J. (2004) · Clinical Infectious Diseases · doi:10.1086/380125 · Cited by 156
Discovery of a Small Molecule that Blocks Wall Teichoic Acid Biosynthesis in Staphylococcus aureus
Swoboda, J. G., Meredith, T. C., Campbell, J., Brown, S. L., Suzuki, T., Bollenbach, T., Malhowski, A. J., Kishony, R., Gilmore, M. S., & Walker, S. (2009) · ACS Chemical Biology · doi:10.1021/cb900151k · Cited by 152
Ceftaroline fosamil: a new broad-spectrum cephalosporin
Laudano, J. B. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr095 · Cited by 147
McKinney, T. K., Sharma, V. K., Craig, W. A., & Archer, G. L. (2001) · Journal of Bacteriology · doi:10.1128/jb.183.23.6862-6868.2001 · Cited by 145
Taking aim at wall teichoic acid synthesis: new biology and new leads for antibiotics
Sewell, E. W., & Brown, E. D. (2013) · The Journal of Antibiotics · doi:10.1038/ja.2013.100 · Cited by 143
Staphylococcus aureus inactivates daptomycin by releasing membrane phospholipids
Pader, V., Hakim, S., Painter, K. L., Wigneshweraraj, S., Clarke, T. B., & Edwards, A. M. (2016) · Nature Microbiology · doi:10.1038/nmicrobiol.2016.194 · Cited by 142
Quinupristin/dalfopristin: A therapeutic review
Allington, D. R., & Rivey, M. P. (2001) · Clinical Therapeutics · doi:10.1016/s0149-2918(01)80028-x · Cited by 140
Discovery of Wall Teichoic Acid Inhibitors as Potential Anti-MRSA β-Lactam Combination Agents
Wang, H., Gill, C., Lee, S. H., Mann, P. A., Zuck, P. D., Meredith, T. C., Murgolo, N., She, X., Kales, S., Liang, L., et al. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.11.013 · Cited by 136
Rouch, D. A., Messerotti, L. J., Loo, L. S. L., Jackson, C. A., & Skurray, R. A. (1989) · Molecular Microbiology · doi:10.1111/j.1365-2958.1989.tb01805.x · Cited by 131
The Ribosomal S10 Protein Is a General Target for Decreased Tigecycline Susceptibility
Beabout, K., Hammerstrom, T. G., Perez, A. M., Magalhães, B. D. F., Prater, A. G., Clements, T. P., Arias, C. A., Saxer, G., & Shamoo, Y. E. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00547-15 · Cited by 129
The evolution of vancomycin intermediate Staphylococcus aureus (VISA) and heterogenous-VISA
Howden, B. P., Peleg, A. Y., & Stinear, T. P. (2014) · Infection, Genetics and Evolution · doi:10.1016/j.meegid.2013.03.047 · Cited by 128
Mechanism of Tet(O)‐mediated tetracycline resistance
Connell, S. R., Trieber, C. A., Dinos, G. P., Einfeldt, E., Taylor, D. E., & Nierhaus, K. H. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg093 · Cited by 127 · cited 1×
“The TetO/Mprotein binds to the EF-G binding site on the ribosome in the post-translocation state and dislodges bound Tet from the A site (Connell et al. 2003a,b).”
BackgroundWichelhaus, T. A., Schäfer, V., Brade, V., & Böddinghaus, B. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.11.2813 · Cited by 126
Kaul, M., Mark, L., Zhang, Y., Parhi, A. K., Lyu, Y. L., Pawlak, J., Saravolatz, S. N., Saravolatz, L. D., Weinstein, M. P., LaVoie, E. J., et al. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00708-15 · Cited by 124
Kim, C. K., Mwangi, M. M., Chung, M., Milheiriço, C., de LENCASTRE, H., & Tomasz, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082814 · Cited by 121
TESTA, R. T., Petersen, P. J., Jacobus, N. V., Sum, P., LEE, V. J., & Tally, F. P. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.11.2270 · Cited by 121
Kaplan, N., Albert, M., Awrey, D. E., Bardouniotis, E., Berman, J., Clarke, T. E., Dorsey, M., Hafkin, B., Ramnauth, J., Romanov, V., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01411-12 · Cited by 120
Molecular basis of fusB‐mediated resistance to fusidic acid in Staphylococcus aureus
O’Neill, A. J., & Chopra, I. (2005) · Molecular Microbiology · doi:10.1111/j.1365-2958.2005.04971.x · Cited by 118
β-Lactam Resistance Mechanisms: Gram-Positive Bacteria and Mycobacterium tuberculosisPreprint
Fisher, J. F., & Mobashery, S. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a025221 · Cited by 116
Nurjadi, D., Olalekan, A. O., Layer, F., Shittu, A. O., Alabi, A. S., Ghebremedhin, B., Schaumburg, F., Hofmann-Eifler, J., van Genderen, P. J. J., Caumes, É., et al. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku174 · Cited by 115
Wormser, G. P., Keusch, G. T., & Heel, R. C. (1982) · Drugs · doi:10.2165/00003495-198224060-00002 · Cited by 114
Small molecule inhibitor of lipoteichoic acid synthesis is an antibiotic for Gram-positive bacteria
Richter, S. G., Elli, D., Kim, H. K., Hendrickx, A. P. A., Sorg, J. A., Schneewind, O., & Missiakas, D. M. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1217337110 · Cited by 113
Oefner, C., Bandera, M., Haldimann, A., Laue, H., Schulz, H., Mukhija, S., Parisi, S., Weiss, L., Lociuro, S., & Dale, G. E. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp024 · Cited by 113
Allignet, J., Loncle, V., Simenel, C., Delepierre, M., & Solh, N. E. (1993) · Gene · doi:10.1016/0378-1119(93)90350-c · Cited by 110
Kadlec, K., & Schwarz, Š. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01128-08 · Cited by 106
Teichoic acid biosynthesis as an antibiotic target
Pasquina, L. W., Maria, J. P. S., & Walker, S. (2013) · Current Opinion in Microbiology · doi:10.1016/j.mib.2013.06.014 · Cited by 104
Yu, J., Grinius, L., & Hooper, D. C. (2002) · Journal of Bacteriology · doi:10.1128/jb.184.5.1370-1377.2002 · Cited by 103
Tedizolid for the Management of Human Infections: In Vitro Characteristics
Locke, J. B., Zurenko, G. E., Shaw, K. J., & Bartizal, K. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/cit616 · Cited by 101 · cited 5×
“The newer oxazolidinone tedilozid is active against strains expressing Cfr resistance because its binding is not occluded by methylation of A2503 (Locke et al. 2014).”
BackgroundInfluentialTruong, Q. C., & Hooper, D. C. (2010) · Journal of Bacteriology · doi:10.1128/jb.00018-10 · Cited by 100
Antibiotics: Challenges, Mechanisms, Opportunities
Walsh, C. T., & Wencewicz, T. A. (2016) · Cited by 99
Lipoprotein nature of Bacillus licheniformis membrane penicillinase.
NIELSEN, J. B. K., Caulfield, M. P., & Lampen, J. O. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.6.3511 · Cited by 97
Dual Targeting of Cell Wall Precursors by Teixobactin Leads to Cell Lysis
Homma, T., Nuxoll, A. S., Gandt, A. B., Ebner, P., Engels, I., Schneider, T., Götz, F., Lewis, K., & Conlon, B. P. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01050-16 · Cited by 96
Truong, Q. C., Ding, Y., & Hooper, D. C. (2008) · Journal of Bacteriology · doi:10.1128/jb.01068-08 · Cited by 92
Dordel, J., Kim, C. K., Chung, M., de la Gándara, M. P., Holden, M. T. G., Parkhill, J., de LENCASTRE, H., Bentley, S. D., & Tomasz, A. (2014) · mBio · doi:10.1128/mbio.01000-13 · Cited by 87
The MUT056399 Inhibitor of FabI Is a New Antistaphylococcal Compound
Escaich, S., Prouvensier, L., Saccomani, M., Durant, L., Oxoby, M., Gerusz, V. J., Moreau, F., Vongsouthi, V., Maher, K., Morrissey, I., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01248-10 · Cited by 84
A Staphylococcus aureus TIR Domain Protein Virulence Factor Blocks TLR2-Mediated NF-κB Signaling
Askarian, F., van Sorge, N. M., Sangvik, M., Beasley, F. C., Henriksen, J. R., Ericson, J. U., van Strijp, J. A. G., Nizet, V., & Johannessen, M. (2014) · Journal of Innate Immunity · doi:10.1159/000357618 · Cited by 83
Matsuo, M., Cui, L., Kim, J., & Hiramatsu, K. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00425-13 · Cited by 83
Crystal Structure of 7,8-Dihydropteroate Synthase from Bacillus anthracis
Babaoglu, K., Qi, J., Lee, R. E., Jr., & White, S. W. (2004) · Structure · doi:10.1016/j.str.2004.07.011 · Cited by 80
Dhand, A., & Sakoulas, G. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.09.005 · Cited by 80
Park, H. S., Yoon, Y. M., Jung, S. J., Kim, C. M., Kim, J. M., & Kwak, J. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm236 · Cited by 77
Conversion of Oxacillin-Resistant Staphylococci from Heterotypic to Homotypic Resistance Expression
Finan, J. E., Rosato, A. E., Dickinson, T. M., Ko, D., & Archer, G. L. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.1.24-30.2002 · Cited by 76
Contemporary unconventional clinical use of co-trimoxazole
Goldberg, E., & Bishara, J. (2011) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03613.x · Cited by 75
Huang, J., Chen, L., Wu, Z., & Wang, L. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw488 · Cited by 73
Müller, S., Wolf, A. J., Iliev, I. D., Berg, B. L., Underhill, D. M., & Liu, G. Y. (2015) · Cell Host & Microbe · doi:10.1016/j.chom.2015.10.011 · Cited by 72
Mukhtar, T. A., Koteva, K. K., Hughes, D. W., & Wright, G. D. (2001) · Biochemistry · doi:10.1021/bi0106787 · Cited by 70
A Pathogen-Selective Antibiotic Minimizes Disturbance to the Microbiome
Yao, J., Carter, R. A., Vuagniaux, G., Barbier, M., Rosch, J. W., & Rock, C. O. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00535-16 · Cited by 69
Berti, A. D., Theisen, E., Sauer, J., Nonejuie, P., Olson, J., Pogliano, J., Sakoulas, G., Nizet, V., Proctor, R. A., & Rose, W. E. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02071-15 · Cited by 68
Renzoni, A., Kelley, W. L., Rosato, R. R., Martínez, M. P. S., Roch, M., Fatouraei, M., Haeusser, D. P., Margolin, W., Fenn, S. J., Turner, R. D., et al. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01634-16 · Cited by 66
The ABC of Ribosome-Related Antibiotic Resistance
Wilson, D. N. (2016) · mBio · doi:10.1128/mbio.00598-16 · Cited by 65
Ribosome clearance by FusB-type proteins mediates resistance to the antibiotic fusidic acid
Cox, G., Thompson, G. S., Jenkins, H. T., Peske, F., Savelsbergh, A., Rodnina, M. V., Wintermeyer, W., Homans, S. W., Edwards, T. A., & O’Neill, A. J. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1117275109 · Cited by 63
Katayama, Y., Sekine, M., Hishinuma, T., Aiba, Y., & Hiramatsu, K. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00420-16 · Cited by 63
Sekiguchi, J., Tharavichitkul, P., Miyoshi‐Akiyama, T., Chupia, V., Fujino, T., Araake, M., Irie, A., Morita, K., Kuratsuji, T., & Kirikae, T. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.9.3948-3951.2005 · Cited by 58
Schaumburg, F., Peters, G., Alabi, A. S., Becker, K., & Idelevich, E. A. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv325 · Cited by 58
Truong, Q. C., Bolduc, G. R., Okumura, R., Celino, B., Bevis, J., Liao, C., & Hooper, D. C. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00289-11 · Cited by 57
Baines, S. L., Howden, B. P., Heffernan, H., Stinear, T. P., Carter, G. P., Seemann, T., Kwong, J. C., Ritchie, S. R., & Williamson, D. A. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03020-15 · Cited by 56
Nagel, M., Reuter, T., Jansen, A., Szekat, C., & Bierbaum, G. (2010) · International Journal of Medical Microbiology · doi:10.1016/j.ijmm.2010.08.021 · Cited by 54
Shore, A. C., Lazaris, A., Kinnevey, P. M., Brennan, O. M., Brennan, G. I., O'Connell, B. C., Feßler, A. T., Schwarz, Š., & Coleman, D. C. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02949-15 · Cited by 54
New Gram-Positive Agents: the Next Generation of Oxazolidinones and Lipoglycopeptides
Crotty, M. P., Krekel, T., Burnham, C. D., & Ritchie, D. J. (2016) · Journal of Clinical Microbiology · doi:10.1128/jcm.03395-15 · Cited by 53
Allignet, J., & Solh, N. E. (1999) · Plasmid · doi:10.1006/plas.1999.1412 · Cited by 50
Truong, Q. C., Hsing, L. C., Villet, R. A., Bolduc, G. R., Estabrooks, Z., Taguezem, G. F., & Hooper, D. C. (2012) · Journal of Bacteriology · doi:10.1128/jb.06503-11 · Cited by 46
Haroche, J., Morvan, A., Davi, M., Allignet, J., Bimet, F., & Solh, N. E. (2003) · Journal of Clinical Microbiology · doi:10.1128/jcm.41.2.586-591.2003 · Cited by 44
Predominance of dfrG as determinant of trimethoprim resistance in imported Staphylococcus aureus
Nurjadi, D., Schäfer, J., Friedrich-Jänicke, B., Müeller, A., Neumayr, A. L. C., Cano, A. C., Goorhuis, A., Molhoek, N., Lagler, H., Kantele, A., et al. (2015) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2015.08.021 · Cited by 42
Yao, J., & Rock, C. O. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a027045 · Cited by 39
Patot, S., Imbert, P. R. C., Baude, J., Martins-Simões, P., Campergue, J.-B., Louche, A., Nijland, R., Bes, M., Tristan, A., Laurent, F. J., et al. (2017) · PLoS Pathogens · doi:10.1371/journal.ppat.1006092 · Cited by 39
Furi, L., Haigh, R., AL-Jabri, Z., Morrissey, I., Ou, H., León‐Sampedro, R., Martínez, J. L., Coque, T. M., & Oggioni, M. R. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.01008 · Cited by 38
Flamm, R. K., Rhomberg, P. R., Kaplan, N., Jones, R. N., & Farrell, D. J. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05119-14 · Cited by 37
Plasmid-mediated florfenicol resistance in Pasteurella trehalosi
Kehrenberg, C., Meunier, D., Targant, H., Cloeckaert, A., Stefan, S., & Madec, J.-Y. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl174 · Cited by 35
Krievins, D. K., Brandt, R., Hawser, S., Hadváry, P., & Islam, K. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01383-08 · Cited by 34
Tomlinson, J. H., Thompson, G. S., Kalverda, A. P., Zhuravleva, A., & O’Neill, A. J. (2016) · Scientific Reports · doi:10.1038/srep19524 · Cited by 34
Adjunctive rifampicin may improve outcomes in Staphylococcus aureus bacteraemia: a systematic review
Russell, C. D., McLean, A. L., Saunders, C., & Laurenson, I. F. (2014) · Journal of Medical Microbiology · doi:10.1099/jmm.0.072280-0 · Cited by 31
Overcoming scientific and structural bottlenecks in antibacterial discovery and development
Zorzet, A. (2014) · Upsala Journal of Medical Sciences · doi:10.3109/03009734.2014.897277 · Cited by 29
Thwaites, G. E., Auckland, C., Barlow, G. D., Cunningham, R., Davies, G., Edgeworth, J. D., Greig, J. M., Hopkins, S., Jeyaratnam, D., Jenkins, N., et al. (2012) · Trials · doi:10.1186/1745-6215-13-241 · Cited by 26
Lahiri, S. D., & Alm, R. A. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv329 · Cited by 25
Yu, F., Lu, C., Liu, Y., Sun, H., Shang, Y., Ding, Y., Li, D., Qin, Z., Parsons, C. H., Huang, X., et al. (2014) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2014.06.020 · Cited by 18
Cited by
Antimicrobial Resistance: A Growing Serious Threat for Global Public Health
Salam, M. A., Al-Amin, M. Y., Salam, M. T., Pawar, J. S., Akhter, N., Rabaan, A. A., & Alqumber, M. A. A. (2023) · Healthcare · doi:10.3390/healthcare11131946 · Cited by 2,338
Antibiotic resistance in microbes: History, mechanisms, therapeutic strategies and future prospects
Uddin, T. M., Chakraborty, A. J., Khusro, A., Zidan, B. R. M., Mitra, S., Emran, T. B., Dhama, K., Ripon, M. K. H., Gajdács, M., Sahibzada, M. U. K., et al. (2021) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2021.10.020 · Cited by 1,311
Prevalence and Therapies of Antibiotic-Resistance in Staphylococcus aureus
Guo, Y., Song, G., Sun, M., Wang, J., & Wang, Y. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.00107 · Cited by 870
Antibiotic resistance and persistence—implications for human health and treatment perspectives
Huemer, M., Mairpady Shambat, S., Brugger, S. D., & Zinkernagel, A. S. (2020) · The EMBO Reports · doi:10.15252/embr.202051034 · Cited by 850
Chaturvedi, P., Shukla, P., Giri, B. S., Chowdhary, P., Chandra, R., Gupta, P., & Pandey, A. (2021) · Environmental Research · doi:10.1016/j.envres.2020.110664 · Cited by 709
Metadata
- Authors
- Foster, T. J.
- Venue
- FEMS Microbiology Reviews
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-04-13
- Volume
- 41
- Issue
- 3
- Pages
- 430-449
- ISSN
- 0168-6445 (ISSN-L)
- 1574-6976
- OpenAlex
- W2605699627
- Cited by
- 845
- References
- 179
- FWCI
- 40.14
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.